Provided by Tiger Trade Technology Pte. Ltd.

HeartSciences Inc

2.99
+0.17006.03%
Post-market: 2.990.00000.00%19:28 EST
Volume:44.70K
Turnover:135.56K
Market Cap:9.50M
PE:-0.43
High:3.19
Open:2.85
Low:2.85
Close:2.82
52wk High:6.47
52wk Low:2.01
Shares:3.18M
Float Shares:3.06M
Volume Ratio:2.13
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8747
EPS(LYR):-9.3420
ROE:-220.42%
ROA:-74.78%
PB:2.27
PE(LYR):-0.32

Loading ...

University of West England Adopts HeartSciences MyoVista ECG Platform

Reuters
·
Feb 05

HeartSciences Wins Cibolo Health Endorsement for MyoVista Insights ECG Platform

Reuters
·
Jan 29

HeartSciences Secures $3.6 Million Unsecured Loan from Streeterville Capital

Reuters
·
Jan 17

HeartSciences Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 22, 2025

Heart Test Laboratories Q2 EPS $(0.85) Beats $(1.69) Estimate, Sales $2.419M Beat $50.000K Estimate

Benzinga
·
Dec 16, 2025

HeartSciences Inc. reports no meaningful revenue and cash of USD 2.0 million for Q2

Reuters
·
Dec 16, 2025

HeartSciences Submits MyoVista wavECG Device for FDA 510(k) Review

Reuters
·
Dec 15, 2025

Heartsciences Announces FDA 510(K) Submission for Myovista® Wavecg™ Device

THOMSON REUTERS
·
Dec 15, 2025

Heartsciences Inc. Announces Unregistered Sale of Equity Securities

Reuters
·
Nov 29, 2025

BRIEF-HeartSciences Enters Amendment No. 7 To Loan Agreement - SEC Filing

Reuters
·
Oct 02, 2025

Heartsciences Inc - Maturity Date of Note Extended to September 30, 2026 - SEC Filing

THOMSON REUTERS
·
Oct 02, 2025

Heartsciences Inc - Enters Amendment No. 7 to Loan Agreement - SEC Filing

THOMSON REUTERS
·
Oct 02, 2025

HeartSciences Inc. Extends Loan Maturity to 2026 in Amended Financing Agreement with Front Range Ventures

Reuters
·
Oct 02, 2025

HeartSciences Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Oct 01, 2025

Heartsciences Inc - Reports No Meaningful Revenue for Fq1 2026

THOMSON REUTERS
·
Sep 12, 2025

Heart Test Laboratories Q1 EPS $(1.58) Beats $(2.09) Estimate, Sales $1.900M

Benzinga
·
Sep 12, 2025

Heartsciences Inc. Reports Minimal Revenues for Q3 2025; Research and Development Expenses Decrease by 19% Compared to Q3 2024

Reuters
·
Sep 12, 2025

Heartsciences Inc. Announces Conversion of Preferred Shares and Debt Exchange, Issuing Over 2.6 Million Shares of Common Stock

Reuters
·
Sep 08, 2025

HeartSciences Inc. Announces Conversion of Preferred Shares and Debt Exchange, Reducing Principal by $1.65 Million

Reuters
·
Aug 23, 2025